This won’t hurt a bit – NMR-based metabolomics in medical diagnosis of prostate cancer

Schirra, H. J., Roberts, M. J., Lavin, M. F. and Gardiner, R. A. (2011). This won’t hurt a bit – NMR-based metabolomics in medical diagnosis of prostate cancer. In: 7th International Conference of the Metabolomics Society, Cairns, Australia, (144-144). 27 - 30 June 2011.

Attached Files (Some files may be inaccessible until you login with your UQ eSpace credentials)
Name Description MIMEType Size Downloads
Author Schirra, H. J.
Roberts, M. J.
Lavin, M. F.
Gardiner, R. A.
Title of paper This won’t hurt a bit – NMR-based metabolomics in medical diagnosis of prostate cancer
Conference name 7th International Conference of the Metabolomics Society
Conference location Cairns, Australia
Conference dates 27 - 30 June 2011
Publication Year 2011
Sub-type Poster
Start page 144
End page 144
Total pages 1
Collection year 2012
Language eng
Abstract/Summary Prostate cancer (PCa) is the most common internal male cancer, involving one in 9 Australian men. Early detection including a reliable prognosis of cancer aggressiveness is instrumental in facilitating early treatment. However, the current diagnosis of PCa, involving serum prostate-specific antigen (PSA) testing followed by trans-rectal ultrasound guided (TRUS) biopsy, are highly invasive and not very reliable. The combination of these two methods permits early detection but the PSA test lacks sensitivity and specificity with most patients undergoing invasive biopsies not having cancer detected. Thus, we are trying to develop a non-invasive test for prostate cancer detection that involves reliable, age-independent markers to identify the presence of PCa, indicate tumour aggressiveness and its metastatic risk. We have used NMR-based metabolomics to investigate the metabolic profiles of post-ejaculate urine, collected from > 100 male patients attending the Urology Outpatients Department of the Royal Brisbane and Women's Hospital. The metabolic profiles were correlated via multivariate analysis with standard clinical data (serum PSA/biopsy) to determine metabolites correlated with cancer status and aggressiveness. In addition, the metabolomic results were combined with those from the mRNA markers PCA3 and Hepsin from prostatic cells disaggregated into prostatic fluid and collected following ejaculation. The combination of these genetic markers with metabolomic data was able to discriminate cancer from non-cancer samples, which correlated with an axis of cancer risk and status. Investigation of this clustering revealed currently unknown metabolites of interest. Further investigation of these promising results may identify potential foundations of a non-invasive diagnostic test for the early detection of PCa.
Q-Index Code EX
Q-Index Status Provisional Code
Institutional Status UQ
Additional Notes Poster 215

Version Filter Type
Citation counts: Google Scholar Search Google Scholar
Created: Fri, 21 Oct 2011, 09:15:24 EST by Roheen Gill on behalf of UQ Centre for Clinical Research